Oxcarbazepine (OXC) isone oftherecentantiepileptic and anticonvulsant drugs. The purpose of the present study was to optimize the best formulafor rectal suppositories of OXC. Thesuppositories were formulated successfully , using different types of witepsol, polyethylene glycols (PEGs) and glycerinated gelatin bases, at different ratios and types of suppositories (conventional and hollow-type). The prepared suppositories were evaluated for physical properties like softening, melting time, hardness and dissolution profiles. The study revealed thathollow -type suppositories of witepsol H35,base loaded with oxcarbazepine solution is the most promising formula compared with other rectal suppositories formulas prepared from different hydrophilic bases and mixtures.The selected formula,which contains 100 milligrams oxcarbazepine loaded as a solution in a witepsol H35 hollow-type suppository base, has a softening and melting time of 4 and 12 minutes, respectively.Besides that, 94% of the drug was released within one hour and had a shelf life of 3.1years.
INTRODUCTION
Suppositories are solid dosage forms, intended for insertion intobody orifices where theymelt, soften or dissolve and exert local or systemic effects. 1 Their action dependson the nature of the drug, concentration, vehicle and the rate of absorption.
Many arguments were indicated for choosing therectal routefor drug administration,among them, to avoid patient gastro intestinal tract problems, unpleasant tasting or bad smelling drugs, first pass effect 2 and their convenience for children and unconscious patients. 3 A hollow-type suppository, which has ahollow cavity to accommodate drugs in variousforms such as a powder orsolution,is very effective as a rapid pain reliever 4 or an anxiolytic and tranquillizer therapy. 5 Vaginal administration of hollow-type suppositories containing Ulinastatin was foundto be effective in the prevention of imminent abortion in combination with the oral administration of uterine relaxing therapy. 6 In addition, hollow-type suppositories have some advantages over conventional suppositories as they can carry either powdered or solution forms of drugs, and they eliminate the effect of the heating process on the nature of the drug during the preparation of the conventional suppositories.
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Oxcarbazepineis an antiepileptic drug used in many diseases including convulsion disorders; it is rapidly and completely absorbed from the GIT. The oral bioavailability is affected by food. 8 This investigation wasconcerned with the preparation ofoxcarbazepine as conventional and hollow-type suppositories for rectal administration to achieve the rapid and complete release of the drug.
EXPERIMENTAL Materials
The materials that were used in this study are listed below: -Oxcarbazepine powder BPwas from Mission Viva Care Limited, Mumbai, India.
Witepsol H35 and witepsol H37 were supplied by Samarra Drug Industry SDI.
Polyethylene glycols PEG (400,1000 and 4000),ethyl oleate and glycerin were supplied byBDH Chemicals Limited, England.
Tween 80 and propylene glycol were supplied by Merck-Schuchardt, Germany.
Lactose, gelatin and liquid paraffin weresupplied by Fluka-AG, Switzerland.
Instruments
The instruments used in this study are as follows: -UV-visible spectrophotometer, Apel UV-VIS PD-303UV, Japan.
- 
Methods

Preparation of Oxcarbazepine Suppositories
Two types of oxcarbazepine suppositories were prepared:
1. Conventional oxcarbazepine suppositories 2. Hollow-type suppositories containing oxcarbazepine in either solution or powder form
Preparation of Oxcarbazepine Conventional Suppositories
The above suppositories were prepared bythe fusion method using different types of suppository bases. The fusion methodinvolved the melting of the base by gentle heating ina water bath,followed bythe addition of the equivalentweight of 100mgoxcarbazepine for each suppository. The melted mass was stirred constantly but slowly to avoid air entrapment, and then the mixture was poured into2 gram suppository moulds.The moulds were allowed to cool thoroughly usinga refrigerator,and any access suppository mass wasremoved from the moulds byscraping. Then the moulds were opened andthe suppositories were removed.
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For suppositories containing the mixture of polyethylene glycol (PEG), the higher molecular weight PEG was first melted, and the lower molecular weight one was added after and mixed well.
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The glycerinated gelatin base was prepared by heating the mixture of gelatin, glycerin and distilled water at 70ºC to dissolve the gelatin , and the mixture was stored in a water bath for 48 hours at 50ºC, and then the mixture was used as a base after the removal of the bubbles.
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Preparation of Hollow-type Suppositories Containing Oxcarbazepine in Solution orPowder Form
Thesetypes of suppositories were prepared by melting various suppository bases using gentle heat in a water bath.The melted bases were poured into 2 gram suppository moulds equipped with acylindrical tube in the center and allowed to stand for 2 hours at room temperature to solidify.
After the construction ofthe hollow-cavity in the solidified bases, oxcarbazepine was added to the cavity in the following forms:
1. Two gramsof mixturepowder prepared by mixing oxcarbazepine andlactose ina percentage 5%(w\w).
2. Four hundred micro liters of (A) oxcarbazepine solution prepared by dissolving the drug in ethyl oleate and then mixed with Tween 80 in a ratio 70:30 w\w, and (B) oxcarbazepine aqueous solution of 4%v\v Tween 80 and the resultant solution was mixedwith propylene glycol in a percentage of 50%v\v for oleaginous bases.
Each suppository contained anamount of solution orpowder equivalent to100mgoxcarbazepine( Table  1) .The openings at the back part of the suppositories were sealed with melted bases.
Physical Properties of the Suppositories Melting Time Estimation
The suppositories wereplaced in a glasstube (2.5 cm in diameter), 2 millilitersof phosphate buffer (pH 7.4) was added, and then the tube was placed in a water bath at 37ºC.The time required foreach suppository to melt completelyor to disintegrate was estimated .
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Rupture Test (Hardness)
This test determinedunder defined conditions the resistance to rupture suppositories measured by the mass needed to rupture them by crushing the hardness tester inside the testing chamber maintained at 25ºC by means of circulating water. The suppository was placed into the holding device with the tip upward andthetestchamber was then closed with a glass plate.At this point the initial load which was given by the entire suspended block was 600 grams. After one minute, a disc of 200 grams was added, and this weight addition was continued every minute until thesuppository's collapse under the load of the weight. Themass required to crush the suppository was calculated by the sum of the masses weighing on the suppository when it was collapsed, and this was assessed as follows:
-If the suppository collapsed within 20 seconds of placingthe last disk, then this mass was not taken intoaccount.
-If the suppository collapsed within 20-40 seconds of placing the last disk, then half of this mass was used in the calculation, i.e., 100 grams.
-If the suppository remained uncrushed for more than 40 seconds, then all the mass was used in the calculation.
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Softening Time Test ofLipophilic Suppositories
The softening time was done by insertingthe suppository in the spiral shaped glass basket of the test tube. A thermostat connected to the tester providedcirculating distilledwater inside the test tube at atemperature of37ºC and constant rate flow.The time required for the first drop of the suppository base to appear floating on the surface was considered as the softening time.
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In Vitro Drug Release
The releaserates of oxcarbazepine from conventional and hollow-type suppositories were determined usingthe basket dissolution apparatus maintained at 50 rpm and temperature 37 ºC. The medium was 500 ml of Sorensen phosphate buffer atpH 7.4.
The time intervals were 0,5,10,15,20,25,30,40,50 and 60 minutes.Four ml samples were withdrawn through a Millipore syringe filter.Theamount of oxcarbazepine was determined using a UV-spectrophotometer at λ max 256.5 nm.
The removed volume of the medium was replaced by the same volume of the buffer solution.The released amount of oxcarbazepine was calculated as a percentage ofdrugs releasedwith time.
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Factors Affecting Formulations Effect of Suppository Type Three types of suppositories were formulated; the first one was aconventional type while thesecond and the third typewere ahollow-type containing oxcarbazepine powder and solution form, respectively. Formula 1, 6 and 11 besides formulas 2, 7 and 12 were selected to demonstrate this effect by using witepsol H35 and witepsol H37 as an oleaginousbase, respectively. Meanwhile formulas 3, 8 and 13and formulas 4, 9 and 14 were selected ashydrophilic bases.Furthermore,formulas 5, 10 and 15 were selected to investigate this effect on glycerinated gelatin based suppositories.
Effect of Suppository Base Type
Lipophilic bases formula 1,2 and hydrophilic bases formula 3, 4 and 5 were used to investigate theeffect of the nature of the suppository base on the physical properties and the in vitrorelease of oxcarbazepine from the prepared suppositories. The investigations were estimated for hollowtype suppositories containing powder and solution as in formulas 6 to 10 and formulas 13 to 15, respectively.
On the other hand,formulas 11 and 12 were studied to show the influence of oleaginousbases on hollow-type suppository bases.
Effect of Storage Time and Temperature on Oxcarbazepine Release from Suppositories
The study was carried out using suppositories stored for 1,15, 30 and 45 days at 25ºC. Formula 11 was wrappedwith aluminum foiland placed in alightly closed container stored atprevious mentioned temperature.
10 Another sample of formula 11
was stored for 30, 60, 120and 180 days at 25ºC to determine the shelflife.
Statistical Analysis
All the results obtainedwere statistically analyzed using one way analysis of variance ANOVA. Differences of (p< 0.05) were considered to be significant. Table 1 shows the effect of changing the type of suppositories on the physical properties of oxcarbazepine suppositories. It was found that themelting time, softening time and hardness for both the hollowtypesuppositories (powder and solution) form, as in formulas 6 and 11, were less than those obtained forthe conventional type,formula 1.Thisreduction may be attributed to the presence of oxcarbazepine containing cavities which might affect the skeletal structureof the hollow-type suppositories .
Table1
36(±0.47) -----------------* (± SD) each represented for three values
RESULTS AND DISCUSSIONS
Effect of Suppository Type on the Physical Properties andOxcarbazepineRelease of the Prepared Suppositories
10 Figure 1 illustrates a significant increase in the release of oxcarbazepine (94%) from solution hollow-type suppositories, formula 11, compared with 3% and 22% for powder hollow-type and conventional suppository base,formulas 6 and 1, respectively.This increase may be in reference tothe fast melting ofthe suppository base and release of the drug faster from the base loaded with the drug solution form. 15 The effect of changing the suppository type on the physical properties and release profile ofoxcarbazepine suppositories prepared from witepsol H37 revealed thata reduction in the melting time, softening time and hardness in both hollow-type suppositories, formulas 7 and 12, compared with the conventional type, formula 2.This reduction may be attributed to the presence of air cavities within the skeleton of the suppository which may affect the physical properties of the suppository base.
10 There wasa significant increase (p< 0.05) in the percentage of the drug release from the solution hollowtype suppository , formula 12, compared with the conventional and powdered hollow-type, formulas 2 and 7, respectively as shown in figure 2. This result may be due to the same effect ofthe fast dissolution of oxcarbazepine fromthe solution compared with the drug dispersed or powder forms. On the other hand, the table and figure 3 show the effect of changing the suppository type on the physical properties and in vitro dissolution rate of the resultant suppositories using PEG400 and PEG4000in a ratio of 70 : 30 as hydrophilic suppository bases as shown in formulas 3, 8 and 13.
The results indicated that the melting time and hardness of the hollow-types suppositories,formulas 8 and 13,were less than those of the conventional type,formula 3.This effect may be attributed to the compact back bone of the conventional type with the more rigid and consolidated structure than the hollow-type.
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In addition, the release profiles of the drug from thesesuppositories revealed no significant (p> 0.05) change in 100% of the drug release from these types.The result is quietly referring to the solubility and partitioning of the drug in the buffered media, and the partition coefficient of the drug with the base used, respectively.
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Meanwhile the times for 50% (T50%) of the drug release were 10, 13 and 4 minutes for formulas 3, 8 and 13, respectively.
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The same results were obtained when PEG400 wasreplaced by PEG 4000 in the suppository base with the same ratio formulas 4, 9and 14, as shown in table 1 and figure 4 sincethe T50% of drug release for these formulas were 12, 14and 7 minutes, respectively.
In addition, the glycerinated gelatin basewhen changing the suppository type, the effect in physical properties andthe release profileareshown in figure5. The results revealed that a decrease in the melting time was aninsignificant (p>0.05) increase in 100% oxcarbazepine release from both the hollow-typescompared withthe conventional one.The T50% drug release illustrated that the solution containing hollow-type suppositories arefaster than those prepared from powder containing hollow-type and conventional suppositories , corresponding to 20, 25 and 13 minutes, respectively.
The same results were obtained when diazepam was incorporated as aliquid and powder statedrug in hollowtype rectal suppositories.
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According toall the above results, Formula 11 was selected as apromised rectalsuppository preparation for further pharmaceutical studies. Figure 6 shows the effect of the storage period at 25ºC on the release behavior of oxcarbazepine . It was clearly revealed that there was no significant change (p>0.05) in 100% of thedrug release. This effect may be attributed to the presence of oxcarbazepine in a hole separated liquid state in the back bone of the hollow suppository that protects the drug itself from any storage environment that affects the base itselfsince the witepsol base when stored at room temperature for a prolonged time may undergo crystallization.
Effect of StorageTime and Temperature on Oxcarbazepine Release FromSelected Formula 11
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Shelf Life of the Selected Formula 11
The selected formula of oxcarbazepine rectal suppositories were introduced fortheir shelf life estimation. The suppositories were stored at 25ºC, and the samples were analyzed for the drug content at 30, 60, 120 and 180 days where the results indicated that the oxcarbazepine degradation followed the first order kinetic with a rate constant K1(25ºC) = 0.093 X10⎯ ³day⎯ ¹, as shown in figure 7. The shelf life calculationwas found to be 3.1 years.
CONCLUSION
Based on the results obtained from this study,one can conclude thefollowing:
-Oxcarbazepine canbe formulated successfully as conventional and hollow-type rectal suppositories.
-Best resultswere obtained when acombination of PEG400 and PEG4000 were used as a water soluble base.
For fast release of oxcarbazepine, hollow-type selected formula 11 was the most promising candidate to be a rectal dosage form with acceptable physical properties and estimated shelf life of 3.1 years. 
